Fibroblast Growth Factor 23 (FGF23) predicts progression of chronic kidney disease: The Mild to Moderate Kidney Disease (MMKD) study

Journal of the American Society of Nephrology

Volumn 18, Issue 9, 2007, Pages 2601-2608

  Fliser, Danilo ^a   Kollerits, Barbara ^b   Neyer, Ulrich ^c   Ankerst, Donna P ^b,d   Lhotta, Karl ^e   Lingenhel, Arno ^b   Ritz, Eberhard ^f   Kronenberg, Florian ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c Academic Teaching Hospital   (Austria)

^d Mays Cancer Center at UT Health San Antonio   (United States)

^e UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^f UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CALCIUM; CREATININE; FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; PHOSPHATE; VITAMIN D; FIBROBLAST GROWTH FACTOR;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; CALCIUM BLOOD LEVEL; CALCIUM METABOLISM; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CREATININE BLOOD LEVEL; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; LABORATORY; MAJOR CLINICAL STUDY; MALE; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PHOSPHATE METABOLISM; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; AGE; BLOOD; CHEMISTRY; CHRONIC DISEASE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PREDICTION AND FORECASTING; TERMINALLY ILL PATIENT;

ADULT; AGE FACTORS; CALCIUM; CHRONIC DISEASE; COHORT STUDIES; CREATININE; DISEASE PROGRESSION; FEMALE; FIBROBLAST GROWTH FACTORS; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY DISEASES; KIDNEY FAILURE; MALE; MIDDLE AGED; PHOSPHATES; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; TERMINALLY ILL;

EID: 34548497123     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2006080936     Document Type: Article

References (33)

1. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15: 2208-2218, 2004
2. Schmitt CP, Odenwald T, Ritz E: Calcium, calcium regulatory hormones, and calcimimetics: Impact on cardiovascular mortality. J Am Soc Nephrol 17[Suppl 2]: S78-S80, 2006
3. Ritz E, Gross ML, Dikow R: Role of calcium-phosphorous disorders in the progression of renal failure. Kidney Int Suppl 99: S66-S70, 2005
4. Berndt TJ, Schiavi S, Kumar R: "Phosphatonins" and the regulation of phosphorus homeostasis. Am J Physiol Renal Physiol 289: F1170-F1182, 2005
5. Tomford RC, Karlinsky ML, Buddington B, Alfrey AC: Effect of thyroparathyroidectomy and parathyroidectomy on renal function and the nephrotic syndrome in rat nephrotoxic serum nephritis. J Clin Invest 68: 655-664, 1981
6. Ogata H, Ritz E, Odoni G, Amann K, Orth SR: Beneficial effects of calcimimetics on progression of renal failure and cardiovascular risk factors. J Am Soc Nephrol 14: 959-967, 2003
7. Christiansen C, Rodbro P, Christensen MS, Hartnack B, Transbol I: Deterioration of renal function during treatment of chronic renal failure with 1,25-dihydroxycholecalciferol. Lancet 2: 700-703, 1978
8. Schwarz U, Amann K, Orth SR, Simonaviciene A, Wessels S, Ritz E: Effect of 1,25(OH)2 vitamin D3 on glomerulosclerosis in subtotally nephrectomized rats. Kidney Int 53: 1696-1705, 1998
9. Panichi V, Migliori M, Taccola D, Filippi C, De Nisco L, Giovannini L, Palla R, Tetta C, Camussi G: Effects of 1,25(OH)2D3 in experimental mesangial proliferative nephritis in rats. Kidney Int 60: 87-95, 2001
10. Weber TJ, Liu S, Indridason OS, Quarles LD: Serum FGF23 levels in normal and disordered phosphorus homeostasis. J Bone Miner Res 18: 1227-1234, 2003
11. Fugakawa M, Kazama JJ: With or without the kidney: The role of FGF23 in CKD. Nephrol Dial Transplant 20: 1295-1298, 2005
12. ADHR Consortium: Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 26: 345-348, 2000
13. Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, Yamamoto T, Hampson G, Koshiyama H, Ljunggren O, Oba K, Yang IM, Miyauchi A, Econs MJ, Lavigne J, Juppner H: Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 348: 1656-1663, 2003
14. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T: Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A 98: 6500-6505, 2001
15. Shimada T, Urakawa I, Yamazaki Y, Hasegawa H, Hino R, Yoneya T, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T: FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem Biophys Res Commun 314: 409-414, 2004
16. Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, Fukumoto S, Tomizuka K, Yamashita T: Targeted ablation of FGF23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 113: 561-568, 2004
17. Ferrari SL, Bonjour JP, Rizzoli R: Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab 90: 1519-1524, 2005
18. Larsson T, Nisbeth U, Ljunggren O, Juppner H, Jonsson KB: Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 64: 2272-2279, 2003
19. Imanishi Y, Inaba M, Nakatsuka K, Nagasue K, Okuno S, Yoshihara A, Miura M, Miyauchi A, Kobayashi K, Miki T, Shoji T, Ishimura E, Nishizawa Y: FGF-23 in patients with end-stage renal disease on hemodialysis. Kidney Int 65: 1943-1946, 2004
20. Shigematsu T, Kazama JJ, Yamashita T, Fukumoto S, Hosoya T, Gejyo F, Fukagawa M: Possible involvement of circulating fibroblast growth factor-23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis 44: 250-256, 2004
21. Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, Juppner H, Wolf M: Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 16: 2205-2215, 2005
22. Nagano N, Miyata S, Abe M, Kobayashi N, Wakita S, Yamashita T, Wada M: Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats. Kidney Int 69: 531-537, 2006
23. Ibels LS, Alfrey AC, Huffer WE, Craswell PW, Anderson JT, Weil R: Arterial calcification and pathology in uremic patients undergoing dialysis. Am J Med 66: 790-796, 1979
24. Block GA, Hulbert-Shearon TE, Levin NW, Port FK: Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 31: 607-617, 1998
25. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK: Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 12: 2131-2138, 2001
26. Giachelli CM, Speer MY, Li X, Rajachar RM, Yang H: Regulation of vascular calcification: Roles of phosphate and osteopontin. Circ Res 96: 717-722, 2005
27. Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, Sherrard DJ, Andress DL: Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 16: 520-528, 2005
28. Narang R, Ridout D, Nonis C, Kooner JS: Serum calcium, phosphorus and albumin levels in relation to the angiographic severity of coronary artery disease. Int J Cardiol 60: 73-79, 1997
29. Tonelli M, Sacks F, Pfeffer M, Gao Z, Curhan G; Cholesterol and Recurrent Events Trial Investigators: Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 112: 2627-2633, 2005
30. Haut LL, Alfrey AC, Guggenheim S, Buddington B, Schrier N: Renal toxicity of phosphate in rats. Kidney Int 17: 722-731, 1980
31. Alfrey AC: The role of abnormal phosphorus metabolism in the progression of chronic kidney disease and metastatic calcification. Kidney Int Suppl 90: S13-S17, 2004
32. Boes E, Fliser D, Ritz E, Konig P, Kraatz G, Lhotta K, Mann JF, Muller GA, Neyer U, Riegel W, Riegler P, Kronenberg F; for the MMKD Study Group: Apolipoprotein A-IV predicts progression of chronic kidney disease: The Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 17: 528-536, 2006
33. Bostom AG, Kronenberg F, Ritz E: Predictive performance of renal function equations for patients with chronic kidney disease and normal serum creatinine levels. J Am Soc Nephrol 13: 2140-2144, 2002